


1. A compound of formula (I) or a pharmaceutically acceptable salt, solvate, or hydrolysable ester thereof,



Wherein:

R^1 and R^2 are independently hydrogen or C_{1-3} alkyl;

X represents a bond, CH_2 or O;

R^3 and R^4 are independently hydrogen, C_{1-6} alkyl, OCH_3 , CF_3 , allyl or halogen;

X^1 is CH_2 , SO_2 , or CO;

R^5 is $-C_{1-6}$ alkyl (optionally substituted by C_{1-6} alkoxy or C_{1-6} alkylthio), $-C_{2-6}$ alkenyl, $-C_{0-6}$ alkyl phenyl (wherein the phenyl is optionally substituted by one or more CF_3 , halogen, C_{1-3} alkyl, C_{1-3} alkoxy), $-COC_{1-6}$ alkyl, SO_2C_{1-6} alkyl ;

R^6 is phenyl or a 6 membered heteroaryl group containing 1,2 or 3 N atoms wherein the phenyl or heteroaryl group is optionally substituted with 1, 2 or 3 moieties selected from the group consisting of C_{1-6} alkyl, halogen, $-OC_{1-6}$ alkyl, $-SO_2C_{1-3}$ alkyl, phenyl (optionally substituted by one or more groups selected from halogen, CF_3 , C_{1-3} alkyl, OC_{1-3} alkyl, acetyl, CN).

2. A compound according to claim 1 wherein each R^1 and R^2 is independently H or methyl.

3. A compound according to claim 2 wherein R^1 and R^2 are both H or both methyl.

4. A compound according to claim 3 wherein R^1 and R^2 are both H.

5. A compound according to claims 1-4 wherein X is O.

6. A compound according to claims 1- 5 wherein R^3 and R^4 are independently H or C_{1-3} alkyl.

7. A compound according to claim 6 wherein one of R^3 and R^4 is H and the other is C_{1-3} alkyl.

8. A compound according to claim 7 wherein the C₁₋₃ alkyl group is positioned ortho to the X moiety.

9. A compound according to claims 1-8 wherein X¹ is CH₂.

10. A compound according to claims 1-9 wherein R⁵ is butyl or methoxyethyl.

11. A compound according to claims 1-10 wherein R⁶ is phenyl or a 6-membered heterocycle selected from pyrimidine, pyridine, pyridazine and pyrazine each of which phenyl or heterocycle is substituted by phenyl (optionally substituted by one or more CF₃, C₁₋₃ alkyl, halogen, CN) and optionally a further C₁₋₃ alkyl substituent.

12. A compound according to claim 11 wherein the phenyl, (optionally substituted by one or more CF₃, C₁₋₃ alkyl, halogen, CN) is in the meta position to the depicted N.

13. A compound according to claim 1 selected from:

2-Methyl-2-{2-methyl-4-[[4-(trifluoromethyl)benzyl]{6-[4-(trifluoromethyl)phenyl]pyridin-2-yl}amino)methyl}phenoxy}propanoic acid

2-{4-[(Butyl{6-[4-(trifluoromethyl)phenyl]pyridin-2-yl}amino) methyl]-2-methylphenoxy}-2-methylpropanoic acid

{4-[(Butyl{6-[4-(trifluoromethyl)phenyl]pyridin-2-yl}amino)methyl]-2-methylphenoxy}acetic acid

[4-((Butyl[4'-(trifluoromethyl)-1,1'-biphenyl-3-yl]amino)methyl)-2-methylphenoxy]acetic acid

[4-((2-Methoxyethyl)[4'-(trifluoromethyl)-1,1'-biphenyl-3-yl]amino)methyl)-2-methylphenoxy]acetic acid

[2-Methyl-4-((pentyl[4'-(trifluoromethyl)-1,1'-biphenyl-3-yl]amino)methyl)phenoxy]acetic acid

[4-((2-Cyclopropylethyl)[4'-(trifluoromethyl)-1,1'-biphenyl-3-yl]amino)methyl)-2-methylphenoxy]acetic acid

[2-Methyl-4-((propyl[4'-(trifluoromethyl)-1,1'-biphenyl-3-yl]amino)methyl)phenoxy]acetic acid

[2-Methyl-4-((2-(methylthio)ethyl)[4'-(trifluoromethyl)-1,1'-biphenyl-3-yl]amino)methyl)phenoxy]acetic acid

[4-((Butyl[2-methyl-4'-(trifluoromethyl)-1,1'-biphenyl-3-yl]amino)methyl)-2-methylphenoxy]acetic acid

[4-((2-Methoxyethyl)[2-methyl-4'-(trifluoromethyl)-1,1'-biphenyl-3-yl]amino)methyl)-2-methylphenoxy]acetic acid

[4-((Butyl[4'-(trifluoromethyl)-1,1'-biphenyl-3-yl]amino)methyl)-2-methylphenoxy]acetic acid

[2-Methyl-4-({(propylsulfonyl)[4'-(trifluoromethyl)-1,1'-biphenyl-3-yl]amino}methyl)phenoxy]acetic acid

[4-({Butyl[4'-(trifluoromethyl)-1,1'-biphenyl-3-yl]amino}sulfonyl)-2-methylphenoxy]acetic acid

[2-Methyl-4-({pentyl[4'-(trifluoromethyl)-1,1'-biphenyl-3-yl]amino}sulfonyl)phenoxy]acetic acid

[4-({(2-Cyclopropylethyl)[4'-(trifluoromethyl)-1,1'-biphenyl-3-yl]amino}sulfonyl)-2-methylphenoxy]acetic acid

{4-[(Butyl{4-[4-(trifluoromethyl)phenyl]pyrimidin-2-yl}amino)methyl]-2-methylphenoxy}acetic acid

[4-({Butyl[4-(4-chlorophenyl)pyrimidin-2-yl]amino}methyl)-2-methylphenoxy]acetic acid

{4-[(2-Methoxyethyl){4-[4-(trifluoromethyl)phenyl]pyrimidin-2-yl}amino)methyl]-2-methylphenoxy}acetic acid

(4-[[4-(4-Chlorophenyl)pyrimidin-2-yl](2-methoxyethyl)amino]methyl)-2-methylphenoxy}acetic acid

{2-Methyl-4-[(propyl{4-[4-(trifluoromethyl)phenyl]pyrimidin-2-yl}amino)methyl]phenoxy}acetic acid

{4-[(Butyl{6-[4-(trifluoromethyl)phenyl]pyrazin-2-yl}amino)methyl]-2-methylphenoxy}acetic acid

[4-({Butyl[6-(4-methylphenyl)pyrazin-2-yl]amino}methyl)-2-methylphenoxy]acetic acid

{4-[(2-Methoxyethyl){6-[4-(trifluoromethyl)phenyl]pyrazin-2-yl}amino)methyl]-2-methylphenoxy}acetic acid

(4-[[Butyl(2,4'-dimethyl-1,1'-biphenyl-3-yl)amino]methyl]-2-methylphenoxy)acetic acid

(4-[[Butyl(4'-fluoro-2-methyl-1,1'-biphenyl-3-yl)amino]methyl]-2-methylphenoxy)acetic acid

(4-[[Butyl(4'-cyano-2-methyl-1,1'-biphenyl-3-yl)amino]methyl]-2-methylphenoxy)acetic acid

(4-[[Butyl(4'-methoxy-2-methyl-1,1'-biphenyl-3-yl)amino]methyl]-2-methylphenoxy)acetic acid

(4-[[Butyl(4'-chloro-2-methyl-1,1'-biphenyl-3-yl)amino]methyl]-2-methylphenoxy)acetic acid

(4-[[{(4'-Chloro-2-methyl-1,1'-biphenyl-3-yl)(2-methoxyethyl)amino]methyl]-2-methylphenoxy}acetic acid

(4-[[{(2,4'-Dimethyl-1,1'-biphenyl-3-yl)(2-methoxyethyl)amino]methyl]-2-methylphenoxy}acetic acid

(4-[[{(2-Methoxyethyl)(4'-methoxy-2-methyl-1,1'-biphenyl-3-yl)amino]methyl]-2-methylphenoxy}acetic acid

(2-Methyl-4-[[[2-methyl-4'-(trifluoromethyl)-1,1'-biphenyl-3-yl](propyl)amino]methyl]phenoxy)acetic acid

(4-[[{(4'-Chloro-2-methyl-1,1'-biphenyl-3-yl)(propyl)amino]methyl]-2-methylphenoxy}acetic acid

(4-[[{(2,4'-Dimethyl-1,1'-biphenyl-3-yl)(propyl)amino]methyl]-2-methylphenoxy}acetic acid

(4-[[{(4'-Fluoro-2-methyl-1,1'-biphenyl-3-yl)(propyl)amino]methyl]-2-methylphenoxy}acetic acid

(4-[[{(4'-Cyano-2-methyl-1,1'-biphenyl-3-yl)(propyl)amino]methyl]-2-methylphenoxy}acetic acid

(4-[[4'-Methoxy-2-methyl-1,1'-biphenyl-3-yl](propyl)amino] methyl)-2-methylphenoxy)acetic acid

{4-[(Butyl{5-methyl-6-[4-(trifluoromethyl)phenyl]pyrimidin-4-yl}amino)methyl]-2-methylphenoxy}acetic acid

5 [4-[(Butyl[6-(4-methoxyphenyl)-5-methylpyrimidin-4-yl]amino)methyl]-2-methylphenoxy]acetic acid

[4-[(Butyl[5-methyl-6-(4-methylphenyl)pyrimidin-4-yl]amino)methyl]-2-methylphenoxy]acetic acid

10 [4-[(Butyl[6-(4-chlorophenyl)-5-methylpyrimidin-4-yl]amino)methyl]-2-methylphenoxy]acetic acid

[4-[(Butyl[6-(4-chlorophenyl)-2-pyrazin-2-yl]amino)methyl]-2-methylphenoxy]acetic acid

[4-[[6-(4-Chlorophenyl)pyrazin-2-yl][2-(methyloxy)ethyl]amino)methyl]-2-methylphenoxy]acetic acid

15 {2-Methyl-4-[(propyl{6-[4-(trifluoromethyl)phenyl]pyrazin-2-yl}amino)methyl]phenoxy}acetic acid

(2-Methyl-4-[[{5-methyl-6-[4-(trifluoromethyl)phenyl]pyrimidin-4-yl}(propyl)amino]methyl]phenoxy)acetic acid

(4-[[[6-(4-Chlorophenyl)-5-methylpyrimidin-4-yl](propyl)amino]methyl]-2-methylphenoxy)acetic acid

20 (2-Methyl-4-[[[5-methyl-6-(4-methylphenyl)pyrimidin-4-yl](propyl)amino]methyl]phenoxy)acetic acid

(2-Methyl-4-[[{5-methyl-6-[4-(methyloxy)phenyl]pyrimidin-4-yl}(propyl)amino]methyl]phenoxy)acetic acid

{4-[(Butyl{6-[4-(trifluoromethyl)phenyl]pyrazin-2-yl}amino)methyl]-2-ethylphenoxy}acetic acid

25 {2-Ethyl-4-[(2-methyloxyethyl){6-[4-(trifluoromethyl)phenyl]pyrazin-2-yl}amino)methyl]phenoxy}acetic acid

[4-[(Butyl[5-methyl-6-(4-methylphenyl)pyrimidin-4-yl]amino)methyl]-2-ethylphenoxy]acetic acid

30 [4-[(Butyl[2-methyl-4'-(trifluoromethyl)-1,1'-biphenyl-3-yl]amino)sulfonyl]-2-methylphenoxy]acetic acid

[2-Methyl-4-[(propylsulfonyl)[4'-(trifluoromethyl)-1,1'-biphenyl-3-yl]amino)methyl]phenoxy]acetic acid

[4-[(Butyl[6-(4-chlorophenyl)-5-methylpyrimidin-4-yl]amino)methyl]-2-ethylphenoxy]acetic acid

35 {4-[(Butyl[5-methyl-6-[4-(trifluoromethyl)phenyl]pyrimidin-4-yl]amino)methyl]-2-ethylphenoxy}acetic acid

{2-Ethyl-4-[[[2-(methyloxy)ethyl]{4-[4-(trifluoromethyl)phenyl]pyrimidin-2-yl}amino)methyl]phenoxy}acetic acid

{2-Methyl-4-[(2-propen-1-yl{6-[4-(trifluoromethyl)phenyl]pyridin-2-yl}amino)methyl]phenoxy}acetic acid

5

14. A compound according to any of claims 1-13 for use in therapy.

10 15. A pharmaceutical composition comprising a compound according to claim 1-13 together with a pharmaceutically acceptable diluent or carrier.

16. Use of a compound according to claim 1-12 for the manufacture of a medicament for the treatment of a hPPAR disease or condition.

15 17. Use according to claim 16 wherein the hPPAR mediated disease or condition is dyslipidemia, syndrome X, heart failure, hypercholesterolemia, cardiovascular disease, type II diabetes mellitus, type I diabetes, insulin resistance, hyperlipidemia, obesity, anorexia bulimia and anorexia nervosa

20 18. A method of treating a hPPAR mediated disease or condition in a patient comprising the administration of a therapeutically effective amount of a compound according to claims 1-13.

25 19. A method according to claim 18 wherein the hPPAR mediated disease or condition is dyslipidemia, syndrome X, heart failure, hypercholesterolemia, cardiovascular disease, type II diabetes mellitus, type I diabetes, insulin resistance, hyperlipidemia, obesity, anorexia bulimia and anorexia nervosa.